162 related articles for article (PubMed ID: 31376917)
1. Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma.
Kong Z; Li J; Liu Z; Liu Z; Zhao D; Cheng X; Li L; Lin Y; Wang Y; Tian J; Ma W
Clin Radiol; 2019 Oct; 74(10):815.e15-815.e23. PubMed ID: 31376917
[TBL] [Abstract][Full Text] [Related]
2.
Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
[TBL] [Abstract][Full Text] [Related]
3.
Kong Z; Jiang C; Zhu R; Feng S; Wang Y; Li J; Chen W; Liu P; Zhao D; Ma W; Wang Y; Cheng X
Neuroimage Clin; 2019; 23():101912. PubMed ID: 31491820
[TBL] [Abstract][Full Text] [Related]
4. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas.
Han Y; Xie Z; Zang Y; Zhang S; Gu D; Zhou M; Gevaert O; Wei J; Li C; Chen H; Du J; Liu Z; Dong D; Tian J; Zhou D
J Neurooncol; 2018 Nov; 140(2):297-306. PubMed ID: 30097822
[TBL] [Abstract][Full Text] [Related]
6. Multicenter clinical radiomics-integrated model based on [
Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive and real-time proliferative activity estimation based on a quantitative radiomics approach for patients with acromegaly: a multicenter study.
Fan Y; Chai Y; Li K; Fang H; Mou A; Feng S; Feng M; Wang R
J Endocrinol Invest; 2020 Jun; 43(6):755-765. PubMed ID: 31849000
[TBL] [Abstract][Full Text] [Related]
8. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
[TBL] [Abstract][Full Text] [Related]
9. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.
Kim S; Chung JK; Im SH; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):52-9. PubMed ID: 15309332
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an
Wang H; Zhao S; Li L; Tian R
Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
[TBL] [Abstract][Full Text] [Related]
11. Prediction of pathology and survival by FDG PET in gliomas.
Padma MV; Said S; Jacobs M; Hwang DR; Dunigan K; Satter M; Christian B; Ruppert J; Bernstein T; Kraus G; Mantil JC
J Neurooncol; 2003 Sep; 64(3):227-37. PubMed ID: 14558598
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
13. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
[TBL] [Abstract][Full Text] [Related]
14. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
15. Radiomic features predict Ki-67 expression level and survival in lower grade gliomas.
Li Y; Qian Z; Xu K; Wang K; Fan X; Li S; Liu X; Wang Y; Jiang T
J Neurooncol; 2017 Nov; 135(2):317-324. PubMed ID: 28900812
[TBL] [Abstract][Full Text] [Related]
16. Prediction of outcome using pretreatment
Lucia F; Visvikis D; Desseroit MC; Miranda O; Malhaire JP; Robin P; Pradier O; Hatt M; Schick U
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):768-786. PubMed ID: 29222685
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Implications of Total Hemispheric Glucose Metabolism Ratio in Cerebrocerebellar Diaschisis.
Segtnan EA; Grupe P; Jarden JO; Gerke O; Ivanidze J; Christlieb SB; Constantinescu C; Pedersen JE; Houshmand S; Hess S; Zarei M; Gjedde A; Alavi A; Høilund-Carlsen PF
J Nucl Med; 2017 May; 58(5):768-773. PubMed ID: 27789719
[TBL] [Abstract][Full Text] [Related]
18. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
Van Laere K; Ceyssens S; Van Calenbergh F; de Groot T; Menten J; Flamen P; Bormans G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):39-51. PubMed ID: 15309329
[TBL] [Abstract][Full Text] [Related]
20. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
